secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066911
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q1 revenue $18.5M (+67% YoY); reaffirms FY guidance $100-106M
---------------------------------------------------------------------------

- Net loss of $13.9M ($0.53/sh) improved from $18.7M loss ($0.73/sh) in Q1 2024.
- Gross profit margin 84.7%; RECELL-only margin 86.4%; expects ~$2.5M lower quarterly opex going forward.
- Launched RECELL GO mini in Feb; nationwide Cohealyx launch on Apr 1 expanding addressable U.S. market to >$3.5B.
- Obtained OrbiMed revenue covenant waiver for Q1; Q2 trailing 12-month covenant set at $78.0M.
- Expects to generate free cash flow in H2 2025 and achieve GAAP profitability in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017025066911/0000950170-25-066911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017025066911/rcel-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer